U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson's COVID-19 vaccine after six women under 50 given the shot developed rare blood clots, dealing a fresh setback to efforts to tackle the pandemic.
U.S. pauses use of J&J COVID-19 vaccine over rare blood clots, rollout delayed in Europe
By Michael Erman and Manas Mishra
Reuters
(Reuters) - U.S. federal health agencies on Tuesday recommended pausing the use of Johnson & Johnson s COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic.
Johnson & Johnson (J&J) said it would delay rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States.
U.S. pauses use of J&J vaccine over rare blood clots, rollout delayed in Europe
By Michael Erman and Manas Mishra
Reuters
(Reuters) - U.S. federal health agencies on Tuesday recommended pausing use of Johnson & Johnson s COVID-19 vaccine for at least a few days after six women under age 50 developed rare blood clots after receiving the shot, dealing a fresh setback to efforts to tackle the pandemic.
Johnson & Johnson said it would delay rollout of the vaccine to Europe, a week after regulators there said they were reviewing rare blood clots in four recipients of the shot in the United States. South Africa also suspended use of J&J s vaccine.
Read more about US calls for pause on J&J s Covid-19 vaccine after 6 clotting cases on Business Standard. The USFDA said one person had died from the rare blood clotting condition after taking the J&J vaccine and another was in a critical condition